Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuna Mutis

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Hemasphere|October 7, 2025
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levelsWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Molecular Cancer Therapeutics|August 28, 2020
Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell MalignanciesHaihui Lu, Ryan D Molony, Dongshu Chen, et al.
Ebiomedicine|June 28, 2023
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activityIda H Hiemstra, Kim C M Santegoets, Maarten L Janmaat, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
The Lancet. Haematology|January 2, 2026
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trialCharlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, et al.
Hemasphere|May 8, 2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple MyelomaChristie P M Verkleij, Kristine A Frerichs, Marloes E C Broekmans, et al.
Human Molecular Genetics|June 25, 2014
A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathyJonas J W Kuiper, Jessica Van Setten, Stephan Ripke, et al.
Blood|February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapyCharlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Hemasphere|October 7, 2025
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levelsWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Molecular Cancer Therapeutics|August 28, 2020
Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell MalignanciesHaihui Lu, Ryan D Molony, Dongshu Chen, et al.
Ebiomedicine|June 28, 2023
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activityIda H Hiemstra, Kim C M Santegoets, Maarten L Janmaat, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
The Lancet. Haematology|January 2, 2026
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trialCharlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, et al.
Hemasphere|May 8, 2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple MyelomaChristie P M Verkleij, Kristine A Frerichs, Marloes E C Broekmans, et al.
Human Molecular Genetics|June 25, 2014
A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathyJonas J W Kuiper, Jessica Van Setten, Stephan Ripke, et al.
Blood|February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapyCharlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Pageof 11